Intellectual Property India Publishes Patent Application for 'Chemokine Receptor 8 (CCR8) Antibodies' Filed by Ibio, Inc.

MUMBAI, India, May 30 -- Intellectual Property India has published a patent application (202517044229 A) filed by Ibio, Inc., San Diego, on May 7, for 'chemokine receptor 8 (ccr8) antibodies.'

Inventor(s) include Phan, Dillon; Hsu, Tom, Sih-Yuan; Phuong, Tam, Thi, Thanh; Greving, Matthew, P.; Taguchi, Alexander, Tomoaki; Schwartz, Cory; Chen, Jiang; Liu, Gao; Brenner, Martin; Dent, Matthew, William; Moore, Cody Allen; and Potula, Hari Hara S.

The application for the patent was published on May 30, under issue no. 22/2025.

According to the abstract released by the Intellectual Property India: "Provided herein are anti-CCR8 antibodies or antigen binding fragment thereof, which bind to CCR8, wherein the CCR8 is a human CCR8 and the antibody does not bind human CCR4. The anti-CCR8 antibodies or antigen binding fragment of the disclosure are useful for the treatment of cancer diseases through the elimination of regulatory T cells. Also provided herein are methods of use for the anti-CCR8 antibodies or antigen binding fragment thereof."

The patent application was internationally filed on Oct. 19, 2023, under International application No.PCT/US2023/077248.

Disclaimer: Curated by HT Syndication.